Sequential methotrexate–5-fluorouracil treatment of squamous cell carcinoma of the head and neck
Hans Strander
Cancer, 1983
View PDFchevron_right
A phase II trial of cisplatin, methotrexate, levofolinic acid, and 5‐fluorouracil in the treatment of patients with locally advanced, metastatic squamous cell carcinoma of the head and neck
M. Biglietto, Giacomo Carteni
Cancer, 1999
View PDFchevron_right
Phase II trial of dose-dense paclitaxel, cisplatin, 5-fluorouracil, and leucovorin with filgrastim support in patients with squamous cell carcinoma of the head and neck
Daniel Castellano
Cancer, 2004
View PDFchevron_right
Issue 1,2011 of US-China Medical Science.pdf
ADA COMAN
View PDFchevron_right
Feasibility of cisplatin/5-fluorouracil and panitumumab in Japanese patients with squamous cell carcinoma of the head and neck
Makoto Tahara
Japanese journal of clinical oncology, 2014
View PDFchevron_right
Head and Neck Cancers, Version 2.2013
Thomas McCaffrey
Journal of the National Comprehensive Cancer Network
View PDFchevron_right
A phase II evaluation of a 3-hour infusion of paclitaxel (P), cisplatin (CDDP) & 5-fluorouracil (5FU) in patients with advanced or recurrent squamous cell carcinoma of the head & neck (SCCHN): A Southwest Oncology Group Study
Wolfram Samlowski
Journal of Clinical Oncology, 2004
View PDFchevron_right
Neoadjuvant therapy for advanced head and neck cancer with allopurinol-modulated high dose 5-fluorouracil and cisplatin a phase I-II study
David Shimm
Cancer, 1987
View PDFchevron_right
Induction chemotherapy with docetaxel, cisplatin, fluorouracil and l-leucovorin for locally advanced head and neck cancers: a modified regimen for Japanese patients
Andrea Berghold
Anti-Cancer Drugs, 2003
View PDFchevron_right
Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck
Amy Kapp
Cancer, 2016
View PDFchevron_right
Neo-adjuvant chemo-(immuno-)therapy of advanced squamous-cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin + 5-fluorouracil (5FU) with cisplatin + 5FU + recombinant interleukin 2
Alessandro Bianchi
Cancer Immunology Immunotherapy, 1998
View PDFchevron_right
Induction chemotherapy with cisplatin/docetaxel versus cisplatin/5-fluorouracil for locally advanced squamous cell carcinoma of the head and neck: A randomised phase II study
Antonio Rueda Lara
European Journal of Cancer, 2005
View PDFchevron_right
Systemic Chemotherapy with Cisplatin Plus 5-FU (PF) for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN): Efficacy and Safety of a Lower Dose of PF (80/800) at a Single Institution in Japan
Naomi Kiyota
Japanese Journal of Clinical Oncology, 2009
View PDFchevron_right
JNCI Journal of the National Cancer Institute Advance Access published August 17, 2009
Shu-Fang Hsu Schmitz
Journal of the National Cancer Institute
View PDFchevron_right
Carboplatin/5-fluorouracil as an Alternative to Cisplatin/5-Fluorouracil for Metastatic and Recurrent Head and Neck Squamous Cell Carcinoma and Nasopharyngeal Carcinoma
Vincent Chee Ee Phua
Asian Pacific Journal of Cancer Prevention, 2013
View PDFchevron_right
A phase II trial of cisplatin and vinorelbine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
enrique espinosa
Head and Neck-journal for The Sciences and Specialties of The Head and Neck, 2002
View PDFchevron_right
Modified TPEx as First-line Treatment for Recurrent and/or Metastatic Head and Neck Cancer
Yukinori Takenaka
Anticancer Research, 2021
View PDFchevron_right
Cisplatin + Vinorelbine (DDP + VNB) Administered in 60 Cases of Recurrent/Metastatic Salivary Gland Malignancies (RMSGM): Final Report
Mario Airoldi
Annals of Oncology, 2012
View PDFchevron_right
Carboplatin, Continuous Infusion Fluorouracil and Mid-cycle High-dose Methotrexate as Initial Treatment in Patients with Locally Advanced Head and Neck Cancer
Kostas Sombolos
Tumori Journal, 1991
View PDFchevron_right
Toxicities associated with head and neck cancer treatment and oncology-related clinical trials
Stephen Sonis
Current problems in cancer, 2016
View PDFchevron_right
Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I-II feasibility study
Joseph Kerger, Carl Van Laer
Annals of Oncology, 2004
View PDFchevron_right
Docetaxel, Ifosfamide and Cisplatin (DIP) in Squamous Cell Carcinoma of the Head and Neck
Manon Huizing, Jan Van den Brande, Pol Specenier
Anticancer Research, 2009
View PDFchevron_right
Modified bi‐weekly cetuximab‐cisplatin and 5‐FU /leucovorin based regimen for effective treatment of recurrent/metastatic head and neck squamous cell carcinoma to reduce chemotherapy exposure of patients
Jeffrey Weinberger
Cancer Reports, 2021
View PDFchevron_right
Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial
brian stein
The Lancet Oncology, 2013
View PDFchevron_right
Superior clinical response and survival rates with initial bolus of cisplatin and 120 hour infusion of 5-fluorouracil before definitive therapy for locally advanced head and neck cancer
John Jacobs
American Journal of Surgery, 1984
View PDFchevron_right
A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck
Francis Worden
Cancer, 2006
View PDFchevron_right